More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.

This much anticipated Third Edition provides a comprehensive presentation of the global burden and patterns of cancer occurrence, along with new developments in our understanding of cancer causation and prevention. Special attention is given to epidemiologic approaches that incorporate molecular biomarkers based on genomic and other emerging technologies, providing new insights into the role of genetic predisposition and gene-environment interactions in cancer induction. In addition, new chapters are included on social class disparities in cancer incidence and mortality, the role of obesity and physical inactivity in cancer etiology, the potential effects of electromagnetic fields and rediofrequency radiation, and the principles of cancer chemoprevention. The textbook is organized into five sections: Basic Concepts; The Magnitude of Cancer; The Causes of Cancer; Cancer by Tissue of Origin; Cancer Prevention and Control. In this new edition, Drs. David Schottenfeld and Joseph F. Fraumeni, Jr. have enlisted three distinguished Associate Editors: Drs. Jonathan Samet of Johns Hopkins University, Graham Colditz of Harvard University and Alice Whittemore of Stanford University.

Most women who die from cervical cancer, particularly in developing countries, are in the prime of their life. They may be raising children, caring for their family, and contributing to the social and economic life of their town or village. Their death is both a personal tragedy, and a sad and unnecessary loss to their family and their community. Unnecessary, because there is compelling evidence, as this Guide makes clear, that cervical cancer is one of the most preventable and treatable forms of cancer, as long as it is detected early and managed effectively. Unfortunately, the majority of women in developing countries still do not have access to cervical cancer prevention programmes. The consequence is that, often, cervical cancer is not detected until it is too late to be cured. An urgent effort is required if this situation is to be corrected. This Guide is intended to help those responsible for providing services aimed at reducing the burden posed by cervical cancer for women, communities and health systems. It focuses on the knowledge and skills needed by health care providers, at different levels of care.

A guide to recent insights into the genetic and epigenetic parameters of cancer biology and pathology and emerging clinical applications The thoroughly updated second edition of The Biology and Treatment of Cancer, now titled Cancer: Prevention, Early Detection, Treatment and Recovery, goes beyond reviewing the fundamental properties of cancer biology and the relevant issues associated with treatment of the disease. The new edition contains coverage of additional "patient centric" topics and presents cancer biology with selection of topics, facts, and perspectives written in easy-to-understand terms. With contributions from noted experts, the book explores recent advances in the understanding of cancer including breakthroughs in the molecular and cellular basis of cancer and provides strategies for approaching cancer prevention, early detection, and treatment. The authors incorporate recent information on the genetic and epigenetic parameters of cancer biology and pathology with indications of emerging clinical applications. The text offers a unique guide to cancer prevention, early detection, treatment, and recovery for students, caregivers, and most importantly cancer patients. This significant book: Incorporates current insight into the genetic and epigenetic parameters of cancer biology and pathology and information on emerging clinical applications Contains contributions from leaders in cancer research, care, and clinical trials Offers an accessible guide to an accurate and balanced understanding of cancer and the cancer patient Focuses on the importance of cancer prevention, early detection, treatment, and survivorship Written for medical students, students of cancer biology, and caregivers and cancer patients, Cancer: Prevention, Early Detection, Treatment and Recovery offers an authoritative overview of the challenges and opportunities associated with cancer biology, cancer research, and the spectrum of clinical considerations.

The global popularity of herbal supplements and the promise they hold in treating various disease states has caused an unprecedented interest in understanding the molecular basis of the biological activity of traditional remedies. Herbal Medicine: Biomolecular and Clinical Aspects focuses on presenting current scientific evidence of biomolecular ef

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.